Dr. Graff will lead IMV’s research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize clinical success Industry veteran Stanley Frankel, M.D. to advise on clinical development DARTMOUTH, Nova Scotia (BUSINESS WIRE) $IMV #Delive.
Dr. Graff will lead IMV s research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize. | June 9, 2021
Operator
Good morning, and thank you for standing by. Welcome to the IMV Inc. first-quarter 2021 conference call. [Operator instructions] I would now like to hand the conference over to Pierre Labbé, chief financial officer.
Thank you. Please go ahead.
Pierre Labbe
Chief Financial Officer
Thank you, Takke. Good morning, everyone. My name is Pierre Labbé, CFO at IMV, and I m pleased to welcome you to our clinical and operational update and first-quarter financial results conference call. I m joined today by Fred Ors, our chief executive officer; and Andrew Hall, our chief business officer, who will be available for the question-and-answer period at the end of the call.
IMV Inc (IMV) Reports Q1 Loss of $0 10 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 12, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 12, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021.
“We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our second immunother